Immunomedics, Inc. reports positive results from epratuzumab study
Shares of Immunomedics, Inc. (Nasdaq: IMMU) are edging higher in pre-market trading this morning after the biopharmaceutical company reported results from a study showing that its drug epratuzumab slows down the activation of B-cells from patients suffering from systemic lupus erythematosus (SLE), but not normal subjects.
SLE is a chronic autoimmune disease that is potentially debilitating and sometimes fatal as the immune system attacks the body’s cells and tissue, resulting in inflammation and tissue damage. SLE can affect any part of the body, but most often harms the heart, joints, skin, lungs, blood vessels, liver, kidneys and nervous system.
Shares of Immunomedics rose $0.12, or 5.04%, to $2.50 in pre-market trading.
